Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Most molecular cancer therapies act on protein targets but data on the proteome status of patients and cellular models for proteome-guided pre-clinical drug sensitivity studies are only beginning to emerge. Here, we profiled the proteomes of 65 colorectal cancer (CRC) cell lines to a depth of > 10,000 proteins using mass spectrometry. Integration with proteomes of 90 CRC patients and matched transcriptomics data defined integrated CRC subtypes, highlighting cell lines representative of each tumour subtype. Modelling the responses of 52 CRC cell lines to 577 drugs as a function of proteome profiles enabled predicting drug sensitivity for cell lines and patients. Among many novel associations, MERTK was identified as a predictive marker for resistance towards MEK1/2 inhibitors and immunohistochemistry of 1,074 CRC tumours confirmed MERTK as a prognostic survival marker. We provide the proteomic and pharmacological data as a resource to the community to, for example, facilitate the design of innovative prospective clinical trials.

Type

Journal article

Journal

Mol Syst Biol

Publication Date

03/11/2017

Volume

13

Keywords

CPTAC , CRC65, drug response, patient stratification, proteomics, Antineoplastic Agents, Biomarkers, Tumor, Cell Line, Tumor, Colorectal Neoplasms, Drug Resistance, Neoplasm, Gene Expression Regulation, Neoplastic, Gene Regulatory Networks, Humans, Immunohistochemistry, MAP Kinase Kinase 1, MAP Kinase Kinase 2, Pharmacogenetics, Prognosis, Protein Kinase Inhibitors, Proteomics, Signal Transduction, Survival Analysis, c-Mer Tyrosine Kinase